UK Markets open in 6 hrs 56 mins

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
16.80+0.58 (+3.58%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close16.22
Open16.39
Bid6.60 x 900
Ask19.88 x 2200
Day's range15.91 - 17.17
52-week range14.65 - 33.09
Volume253,017
Avg. volume219,109
Market cap716.883M
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Merus to Present at the H.C. Wainwright Global Investment Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the H.C. Wainwright Global Investment Conference. The webcast of the presentation will be available on-demand starting on May 24, 2022 at 7:00 a.m. ET and will be con

  • Globe Newswire

    Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update

    - Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host investor call on Sunday, June 5 at 6:00 p.m. CT- Clinical data update of petosemtamab (Peto) and MCLA-129 planned for second half of 2022 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, ful

  • Globe Newswire

    Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on June 3-7, 2022. The presentation will highlight upd